ResearchOncologyCombined medroxyprogesterone acetate/levonorgestrel–intrauterine system treatment in young women with early-stage endometrial cancer
Section snippets
Patients and Methods
A prospective observational study was conducted from September 2008 to December 2012; 16 patients with EC at CHA Gangnam Medical Center were enrolled. Inclusion criteria were ≤40 years old with the histologically proven well-differentiated endometrioid EC, tumor size <2 cm that was presumed International Federation of Gynecology and Obstetrics stage IA limited to the endometrium, and a strong desire to preserve their fertility.
The histologic diagnosis was made with dilation while the patient
Results
Sixteen eligible subjects were treated with combined oral MPA/LNG-IUS. None of them had any obstetric history; their mean age was 34.8 ± 4.3 years (range, 29–40 years), and their average body mass index was 24.4 ± 5.9 kg/m2 (range, 17.0–36.3 kg/m2). The overall complete remission rate was 87.5% (14/16 patients); the average time to complete remission was 9.8 ± 8.9 months (range, 3–35 months). In the initial 3 months of combined treatment, CR was observed in 25% of patients (4/16 patients); PR
Comment
During the last years, conservative treatments such as the administration of high-dose oral progesterone or progesterone-containing intrauterine system frequently have been proposed for early-stage EC.5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 19 Most studies have reported approximately 57-76% response rates for 100-800 mg of oral progesterone (megestrol acetate or MPA:MPA) per day. Nonetheless and unfortunately, such evidence is not sufficient, particularly for the purposes of
References (20)
- et al.
Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40
Obstet Gynecol
(1997) - et al.
Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome
Cancer Lett
(2001) - et al.
Outcome of fertility sparing treatment with progestins in young patients with endometrial cancer
Obstet Gynecol
(2003) - et al.
Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer
Gynecol Oncol
(2005) - et al.
Intrauterine progesterone treatment of early endometrial cancer
Am J Obstet Gynecol
(2002) - et al.
Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature
Gynecol Oncol
(2005) - et al.
Outcomes of conservative therapy for young women with early endometrial adenocarcinoma
Fertil Steril
(2010) - et al.
Cancer statistics, 2011
CA Cancer J Clin
(2011) - et al.
Fertility-sparing treatment of endometrial cancer: options, outcomes and pitfalls
J Gynecol Oncol
(2012) - et al.
Risk factors for young premenopausal women with endometrial cancer
Obstet Gynecol
(2005)
Cited by (74)
The oncological and reproductive outcomes of fertility-preserving treatments for stage 1 grade 1 endometrial carcinoma: a systematic review and meta-analysis
2024, Journal of Obstetrics and GynaecologyExposure to select PFAS and PFAS mixtures alters response to platinum-based chemotherapy in endometrial cancer cell lines
2023, Environmental Health: A Global Access Science SourceRecurrent endometrial atypical hyperplasia diagnosed by pathological examination of the placenta from a live birth: a case report
2023, BMC Pregnancy and ChildbirthSegmented in vitro fertilization and frozen embryo transfer in levonorgestrel-releasing intrauterine device treated patients with endometrial cancer
2023, Archives of Gynecology and Obstetrics
The authors report no conflict of interest.
Cite this article as: Kim MK, Seong SJ, Kim YS, et al. Combined medroxyprogesterone acetate/levonorgestrel–intrauterine system treatment in young women with early-stage endometrial cancer. Am J Obstet Gynecol 2013;209:358.e1-4.